摘要
目的:探讨黄龙咳喘胶囊联合盐酸莫西沙星治疗急性发作期慢性支气管炎患者效果。方法:选取2022年6月至2024年6月焦作市人民医院收治的62例急性发作期慢性支气管炎患者,应用随机数字表分为两组,分别为单药组(n=31,患者对症治疗基础上联合盐酸莫西沙星治)与联合组(n=31,患者在对症治疗基础上联合黄龙咳喘胶囊及盐酸莫西沙星治疗),观察两组患者数据情况。结果:与单药组患者总有效率74.19%相比,联合组患者96.77%更高(P<0.05);联合组与单药组患者不良反应率分别为6.45%、3.23%,差异不显著(P>0.05);联合组患者症状控制时间明显比常规组更短(P<0.05);治疗前,两组患者用力肺活量(forced vital capacity,FVC)与第1秒用力呼气容积(forced expiratory volume in the first second,FEV1)、FEV1/FVC等肺功能指标、白介素-6(interleukin-6,IL-6)、C反应蛋白(C-reactive protein,CRP)等炎症因子水平、莱赛斯特生活质量问卷(leicester cough questionnaire,LCQ)比较,差异不显著(P>0.05),治疗后两组患者指标均显著改善,联合组患者治疗后各项指标改善程度均优于常规组(P<0.05)。结论:黄龙咳喘胶囊联合盐酸莫西沙星治疗急性发作期慢性支气管炎疗效良好,治疗后患者症状及肺功能均改善,治疗安全可靠。
Objective:To explore the efficacy of Huanglong Kechuan Capsules combined with Moxifloxacin Hydrochloride in treating patients with acute exacerbation of chronic bronchitis.Methods:62 patients with acute exacerbation of chronic bronchitis admitted to Jiaozuo People's Hospital from June 2022 to June 2024 were included in the study and randomly divided into two groups using a random number table:the monotherapy group(n=31,treated with Moxifloxacin Hydrochloride on the basis of symptomatic treatment)and the combination group(n=31,treated with Huanglong Kechuan Capsules and Moxifloxacin Hydrochloride on the basis of symptomatic treatment).The data of the two groups were observed and compared.Results:The total effective rate of the combination group 96.77%was significantly higher than that of the monotherapy group 74.19%(P<0.05).The adverse reaction rates of the combination group and the monotherapy group were 6.45%and 3.23%,respectively(P>0.05).The symptom control time of the combination group was significantly shorter than that of the monotherapy group(P<0.05).Before treatment,there were no significant differences in lung function indicators such as forced vital capacity(FVC),forced expiratory volume in the first second(FEV1)and FEV1/FVC,as well as inflammatory factor levels such as interleukin-6(IL-6)and C-reactive protein(CRP)and the Leicester Cough Questionnaire(LCQ)scores between the two groups(P>0.05).After treatment,all indicators in both groups improved significantly,and the improvement in the combination group was superior to that in the monotherapy group(P<0.05).Conclusion:Huanglong Kechuan Capsules combined with Moxifloxacin hydrochloride have good efficacy in treating acute exacerbation of chronic bronchitis.After treatment,patients'symptoms and lung function improve,and the treatment is safe and reliable.
作者
冯林旭
马星海
沈增强
赵晓光
FENG Linxu;MA Xinghai;SHEN Zengqiang;ZHAO Xiaoguang(Jiaozuo People's Hospital,Office of National Drug Clinical Trial Institution,Jiaozuo 454000,China;Jiaozuo People's Hospital,Clinical Pharmacy Department,Jiaozuo 454000,China;Jiaozuo People's Hospital,Department of Medical Oncology,Jiaozuo 454000,China)
出处
《黑龙江医药科学》
2025年第9期48-50,54,共4页
Heilongjiang Medicine and Pharmacy
基金
河南省医学科技攻关计划(联合共建)项目,编号:LHGJ20191336。
关键词
慢性支气管炎
急性发作期
盐酸莫西沙星
黄龙咳喘胶囊
疗效
肺功能
不良反应
chronic bronchitis
acute exacerbation
Moxifloxacin hydrochloride
Huanglong Kechuan Capsules
efficacy
lung function
adverse reactions
